A comparison of current neuroblastoma chemotherapeutics.
Neuroblastoma is the most common solid tumour in childhood. Modern management includes a biopsy to perform genetic studies. Based on clinical data and Myc-N amplification (MNA), patients are divided in three prognostic groups: the low-risk (Stage 1, 2, 4S without MNA) has an event-free survival (EFS) of > 90% with surgery alone; the intermediate-risk (Stage 3, > 1 year of age, without MNA and Stage 3 and 4 infants without MNA) has an EFS of approximately 80% with mild chemotherapy and surgery; the high-risk group includes Stage 4, > 1 year of age and any stage and age with MNA. These patients are treated with chemotherapy, surgery, megatherapy, irradiation and 13-cis-retinoic acid. With this complex therapy, a 5-year EFS of 30-50% can be obtained.
Castel
Victoria
V
Pediatric Oncology Unit, Hospital Infantil Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain. castel_vic@gva.es
Cañete
Adela
A
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D009447:Neuroblastoma / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D011379:Prognosis; D012307:Risk Factors; D033581:Stem Cell Transplantation
D000970:Antineoplastic Agents; D019797:3-Iodobenzylguanidine